Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 103

  • 3 898 clinical trials
  • 1 548 recruiting
  • 703 conditions
  • 31 countries

Conditions in this area

703 conditions with trials, the busiest first

Non-small cell lung cancer327Breast cancer168Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic105Prostate cancer101Ovarian cancer91Colorectal cancer89Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Malignant melanoma79Chronic lymphocytic leukaemia77Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV57Pancreatic carcinoma57Hormone-refractory prostate cancer56Gastric cancer55Bladder cancer54Endometrial cancer53+679

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 898 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 898 clinical trials

Colorectal cancer stage II+1

Recruiting

Study on Colon Cancer Treatment Using Disodium Levofolinate and Drug Combination for Patients with Operable Stage III and High-Risk Stage II Colon Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Levofolinate
  • Sponsor:Ifom Istituto Fondazione Di Oncologia Molecolare Ets In Breve Ifom Ets

Prostate cancer

Recruiting

Study of High-Dose Radiation Therapy Combined with Goserelin for High-Risk Prostate Cancer Patients Using AI-Based Treatment Planning

Registered drugNo placebo
Countries:CyprusCyprus
  • Participants:18–64 years · 65+ years
  • Substances:Goserelin
  • Sponsor:Linac-Pet Scan Opco Limited

Breast cancer+2

Recruiting

Study on Pembrolizumab and Paclitaxel for Early Triple-Negative Breast Cancer in Patients with High Tumor-Infiltrating Lymphocytes

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel
  • Sponsor:Institut Gustave Roussy

Myelofibrosis

Recruiting

Study for Myelofibrosis Patients Using Ruxolitinib or Ruxolitinib with Other Cancer Treatments

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Incyte Corp.

Skin papilloma

Recruiting

Study on the Effectiveness of Interferon Alfa, Interleukin-1, and Interleukin-2 in Treating Non-Genital Warts in Patients

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Interferon Alfa
  • Sponsor:Labo'Life Belgium

Haematological malignancy

Recruiting

Long-term Safety Study of CRISPR CAR T Cell Therapy for Patients with Blood and Solid Cancers

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic Crispr/Cas9-Mediated Genetically Modified Car T Cells Targeting Cd19 Antigen
  • Sponsor:CRISPR Therapeutics AG

Retinoblastoma

Recruiting

Study on Retinoblastoma Treatment: Evaluating the Effectiveness of Topotecan, Vincristine Sulfate, and Etoposide in Patients Eligible for Conservative Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Carboplatin
  • Sponsor:Institut Curie

Gastrointestinal carcinoma+1

Recruiting

Study on the Safety of Lanreotide and Metformin for Patients with Advanced Gastrointestinal or Lung Carcinoids

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lanreotide
  • Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori

Metastases to central nervous system

Recruiting

Evaluation of Bevacizumab in Patients with Brain Radionecrosis After Radiation Treatment for Brain Metastases

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Institut De Cancerologie De L Ouest

Hormone-refractory prostate cancer

Recruiting

Study on Darolutamide and Radiation Therapy for Patients with Castration-Resistant Prostate Cancer and Oligometastases

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Unicancer

Prostate cancer metastatic

Recruiting

Study of Talazoparib and Enzalutamide combination treatment for patients with metastatic prostate cancer who previously received Abiraterone

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Fundacion Oncosur

Ovarian cancer

Recruiting

Study on the Effectiveness of Niraparib Rechallenge After Surgery in Ovarian Cancer Patients with Limited Metastasis

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Niraparib Tosilate Monohydrate
  • Sponsor:Medica Scientia Innovation Research S.L.

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab462 clinical trialsCarboplatin340 clinical trialsCisplatin285 clinical trialsPaclitaxel263 clinical trialsFluorouracil237 clinical trialsOxaliplatin227 clinical trialsNivolumab217 clinical trialsDexamethasone169 clinical trialsBevacizumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.